Biocortech is dedicated to develop in vitro diagnostic tests for patients suffering from psychiatric disorders.
Biocortech is a privately owned company dedicated to develop in vitro diagnostic tests for stratifying patients suffering from psychiatric disorders and for monitoring their respective treatments.
Biocortech proprietary technologies and assays stem from company’s pioneering efforts on deciphering pharmacological and clinical relevance of receptor editing. Biocortech’s current focus is on developing 5HT2c serotonin receptor editing-related applications for depression (major depressive disorders).
Diagnostic and/or predictive biological test of depression and/or of depression severity (i.e., risk of suicidal behavior)
First clinical trial started early 2009. This pilot trial aims at achieving a proof of concept of the test among a sub-population of patients.
Drug screening assay of predictive neuropsychiatric toxicology of new chemical entities
EDITOX® is a proprietary assay able to characterize the toxic central nervous system (CNS) side effects of drugs (anti-depressant, anti-obesity…) in their preclinical phase. Biocortech is now launching this offer on a fee for service basis.